Search
Search Results
##search.searchResults.foundPlural##
-
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1720PDF: 547HTML: 266 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
911PDF: 494HTML: 176 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1618PDF: 1137HTML: 231 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1334PDF: 1273HTML: 81 -
TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY
3495PDF: 1041HTML: 869 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
441PDF: 219HTML: 32 -
FIRST-PHASE INSULIN RESPONSE (FPIR) TO INTRAVENOUS GLUCOSE TOLERANCE TEST (IVGTT), INSULIN SENSITIVITY AND LONG-TERM FOLLOW-UP IN TRANSFUSION-DEPENDENT BETA-THALASSEMIA (TDT) NORMOGLYCEMIC PATIENTS WITH REDUCED INSULIN SECRETION TO ORAL GLUCOSE TOLERANCE TEST: A PILOT STUDY. The function of the endocrine pancreas in transfusion-dependent ?-thalassemia
7248PDF: 526HTML: 219 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
842PDF: 1001Suppl. Files: 131HTML: 64 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2365PDF: 893HTML: 490 -
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3110PDF: 1106HTML: 1462Untitled: 163Untitled: 151Untitled: 155 -
ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
4030PDF: 1210HTML: 1946Table 1: 177 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4593PDF: 2759HTML: 2253 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3180PDF: 1306HTML: 4110 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
1970PDF: 787HTML: 198 -
Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report Liver involvement in familial Mediterranean fever
1237PDF: 889HTML: 281 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1562PDF: 776HTML: 841jdoe, table 2 infections CML .doc: 177jdoe, table 1 infections CML .doc: 165 -
MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE IN EGYPTIAN CHILDREN
1742PDF: 813HTML: 1130Cover: 170 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2180PDF: 935HTML: 1874 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1787PDF: 697HTML: 2087Untitled: 196Untitled: 141Untitled: 157Untitled: 142Untitled: 148Untitled: 161Untitled: 171







